HUMAN PERINATAL INTERVENTION

人类围产期干预

基本信息

  • 批准号:
    8120336
  • 负责人:
  • 金额:
    $ 26.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-08-01 至 2014-07-31
  • 项目状态:
    已结题

项目摘要

Primary prevention is a goal for the investigation of any chronic illness. Project 2 focuses on translating basic neurobiological findings about the role of alpha 7 nicotinic receptors in early brain development into clinical assessments of early human developmental abnormalities that can progress to schizophrenia later in life. It is also conducting initial tests of a specific perinatal intervention to reduce this risk. We have systematically examined the development of psychophysiological and neuropsychological abnormalities associated with the genetic liability to schizophrenia in adults. These include auditory sensory gating deficits demonstrated with PSO auditory evoked potentials, abnormalities in smooth pursuit eye movements, mismatch negativity, and various measures of attention. Abnormalities in these measures appear in some children of parents with schizophrenia as soon as testing is developmentally possible. Basic science research points to the perinatal period as a critical window for the role of alpha 7 nicotinic receptors, with their maximal expression occurring then as the adult forms of GABA and glutamate synapses are expressed. We developed techniques to record PSO sensory gating within several weeks of birth and showed that this function is already normally present. In the proposed aims, we will extend our initial observation that parental history of psychosis is associated with diminished PSO auditory sensory gating. Project 3 will genotype our subjects to test whether the genetic associations of these deficits in early development are the same as the associations in adults. Similar genetic association may support the hypothesis that the deficits in children at risk for schizophrenia have the same molecular basis as deficits observed in schizophrenia itself. We will also extend a second observation that maternal nicotine use during pregnancy is associated with diminished PSO auditory sensory gating. These effects are additive with the effects of apparent genetic risk and implicate nicotinic receptors in the deficit, as is also true in adults with schizophrenia who respond to chronic nicotine exposure with loss of PSO gating. Based on Project 3's demonstration that perinatal choline, an alpha 7 nicotinic receptor agonist, improves sensory gating in the DBA/2 mouse model of genetic deficiencies in alpha 7 nicotinic receptors and sensory gating, we have obtained FDA permission to administer perinatal choline to mothers and their infants. We will continue this clinical investigation, which shows initial promise of early enhancement of sensory gating. Project 2 receives clinical research support from Project 1 and basic research support from Projects 3,4,5,6. RELEVANCE (See instructions): New therapeutic strategies for schizophrenia are needed to improve cognitive dysfunction and negative symptoms and to prevent the development of psychosis. The Center investigates a nicotinic acetylcholine receptor as a new therapeutic target. Investigational results are used to design a new drug treatment for schizophrenia and a preventative nutrient intervention during infant development, both of which activate this rprpntnr
初级预防是调查任何慢性疾病的目标。项目2侧重于翻译

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT R FREEDMAN其他文献

ROBERT R FREEDMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT R FREEDMAN', 18)}}的其他基金

MOUSE MODEL OF MATERNAL IMMUNE ACTIVATION
母体免疫激活的小鼠模型
  • 批准号:
    8120340
  • 财政年份:
    2010
  • 资助金额:
    $ 26.75万
  • 项目类别:
MOUSE MOLECULAR AND NEUROBIOLOGICAL MODELS
小鼠分子和神经生物学模型
  • 批准号:
    8120338
  • 财政年份:
    2010
  • 资助金额:
    $ 26.75万
  • 项目类别:
ADMINISTRATION AND DATABASE
管理和数据库
  • 批准号:
    8120341
  • 财政年份:
    2010
  • 资助金额:
    $ 26.75万
  • 项目类别:
STATISTICAL GENETICS AND TREATMENT ANALYSIS
统计遗传学和治疗分析
  • 批准号:
    8120342
  • 财政年份:
    2010
  • 资助金额:
    $ 26.75万
  • 项目类别:
HUMAN CHRNA7 MODELS IN MICE
小鼠体内的人类 CHRNA7 模型
  • 批准号:
    8120339
  • 财政年份:
    2010
  • 资助金额:
    $ 26.75万
  • 项目类别:
NICOTINIC CHOLINERGIC RECEPTOR AGONISTS
烟碱胆碱能受体激动剂
  • 批准号:
    8120343
  • 财政年份:
    2010
  • 资助金额:
    $ 26.75万
  • 项目类别:
CHOLINERGIC TREATMENT OF SCHIZOPHRENIA
精神分裂症的胆碱能治疗
  • 批准号:
    8120335
  • 财政年份:
    2010
  • 资助金额:
    $ 26.75万
  • 项目类别:
REGULATION OF CHRNA7 EXPRESSION
CHRNA7表达的调控
  • 批准号:
    8120337
  • 财政年份:
    2010
  • 资助金额:
    $ 26.75万
  • 项目类别:
CHOLINERGIC TREATMENT OF SCHIZOPHRENIA
精神分裂症的胆碱能治疗
  • 批准号:
    8515782
  • 财政年份:
    2009
  • 资助金额:
    $ 26.75万
  • 项目类别:
REGULATION OF CHRNA7 EXPRESSION
CHRNA7表达的调控
  • 批准号:
    7752182
  • 财政年份:
    2009
  • 资助金额:
    $ 26.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了